Robert Doebele
MD, PhD
Chief Medical Officer
👥Biography 个人简介
Robert Doebele was among the first to characterize NTRK fusions in lung cancer and contributed to larotrectinib clinical development. His laboratory at the University of Colorado discovered novel resistance mechanisms to TRK inhibitors. He has transitioned to industry leadership to advance next-generation agents for rare fusion-driven cancers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Robert Doebele 的研究动态
Follow Robert Doebele's research updates
留下邮箱，当我们发布与 Robert Doebele（Rain Therapeutics）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment